AR060991A1 - Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes - Google Patents

Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes

Info

Publication number
AR060991A1
AR060991A1 ARP070102009A ARP070102009A AR060991A1 AR 060991 A1 AR060991 A1 AR 060991A1 AR P070102009 A ARP070102009 A AR P070102009A AR P070102009 A ARP070102009 A AR P070102009A AR 060991 A1 AR060991 A1 AR 060991A1
Authority
AR
Argentina
Prior art keywords
alkyl
diabetes
treatment
difenyl
pyrimidinyl
Prior art date
Application number
ARP070102009A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR060991A1 publication Critical patent/AR060991A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos son adecuados para el tratamiento de la diabetes. Reivindicacion 1: Un compuesto de la formula (1) en la que: R1, R2 son, independientemente uno del otro, alquilo C1-6, O-alquilo C1-6, NH2, NH-alquilo C1-4, N[alquilo C1-4]2, OH, CN, F, Cl, Br, O-fenilo, CF3, OCF3 u OCH3, donde el alquilo puede estar sustituido una o más veces con F, Cl, Br o CN; n es 0, 1, 2, 3, 4 o 5; m es 0, 1, 2, 3, 4 o 5; X es alquinileno C2-10, donde el alquinileno puede estar sustituido una o más veces con R3; R3 es NH2, NH-alquilo C1-4, N[alquilo C1-4]2, F, Cl, Br, CN, OH, O-alquilo C1-6, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6, donde el alquilo, alquenilo y alquinilo pueden estar sustituidos una o más veces con F, Cl, Br o CN; y sus sales fisiologicamente toleradas.
ARP070102009A 2006-05-11 2007-05-09 Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes AR060991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006021873 2006-05-11

Publications (1)

Publication Number Publication Date
AR060991A1 true AR060991A1 (es) 2008-07-30

Family

ID=38370354

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102009A AR060991A1 (es) 2006-05-11 2007-05-09 Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes

Country Status (17)

Country Link
US (1) US7709490B2 (es)
EP (1) EP2024338B1 (es)
JP (1) JP2009536628A (es)
KR (1) KR20090006847A (es)
CN (1) CN101421248A (es)
AR (1) AR060991A1 (es)
AT (1) ATE441638T1 (es)
AU (1) AU2007250212A1 (es)
BR (1) BRPI0711416A2 (es)
CA (1) CA2651658A1 (es)
DE (1) DE502007001453D1 (es)
IL (1) IL195176A0 (es)
MX (1) MX2008014204A (es)
NO (1) NO20085067L (es)
TW (1) TW200817339A (es)
UY (1) UY30337A1 (es)
WO (1) WO2007131621A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2430004B1 (en) * 2009-05-12 2013-07-17 Actelion Pharmaceuticals Ltd. Novel oxazolidinone derivatives and their use as orexin receptor antagonists
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
CN106279041A (zh) * 2016-08-16 2017-01-04 四川思睿博生物科技有限公司 苯基嘧啶衍生物及其制备方法和用途
PE20210640A1 (es) 2018-02-13 2021-03-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
ES2962674T3 (es) 2018-07-13 2024-03-20 Gilead Sciences Inc Inhibidores PD-1/PD-L1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6696474B2 (en) * 2002-04-03 2004-02-24 Warner Lambert Co. Llc. Antidiabetic agents

Also Published As

Publication number Publication date
NO20085067L (no) 2009-02-06
BRPI0711416A2 (pt) 2011-11-01
CN101421248A (zh) 2009-04-29
TW200817339A (en) 2008-04-16
EP2024338A1 (de) 2009-02-18
JP2009536628A (ja) 2009-10-15
IL195176A0 (en) 2009-08-03
MX2008014204A (es) 2008-11-14
CA2651658A1 (en) 2007-11-22
WO2007131621A1 (de) 2007-11-22
AU2007250212A1 (en) 2007-11-22
UY30337A1 (es) 2008-01-02
EP2024338B1 (de) 2009-09-02
DE502007001453D1 (de) 2009-10-15
US7709490B2 (en) 2010-05-04
KR20090006847A (ko) 2009-01-15
US20090149477A1 (en) 2009-06-11
ATE441638T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
AR060991A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes
AR060992A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemia
AR060990A1 (es) Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes
AR068479A1 (es) (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica
CO6290631A2 (es) Composición oral que contiene amino ácidos y un agente blanqueador
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
AR061968A1 (es) Ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-i-il-piridin-3-il-amino)-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos
AR061238A1 (es) Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c
CL2009001059A1 (es) Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
AR082444A1 (es) Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
AR049588A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de receptores ptp1b
AR063925A1 (es) Antibacteriales 5-hidroximetil -oxazolidin-2-ona composicion farmaceutica que los comprende y su uso para tratar o prevenir infecciones bacterianas
CO6300946A2 (es) Forma cristalina de derivado de fenilamino pirimidina
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
PE20080370A1 (es) Derivados de quinazolinona como antagonistas de cgrp
CL2011001413A1 (es) Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana.

Legal Events

Date Code Title Description
FB Suspension of granting procedure